IDEAYA Biosciences, Inc. $IDYA Shares Acquired by Fiera Capital Corp

Fiera Capital Corp boosted its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 20.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,837,967 shares of the company’s stock after acquiring an additional 305,698 shares during the quarter. Fiera Capital Corp owned 2.10% of IDEAYA Biosciences worth $50,011,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. Arizona State Retirement System raised its holdings in shares of IDEAYA Biosciences by 1.5% in the 3rd quarter. Arizona State Retirement System now owns 23,324 shares of the company’s stock worth $635,000 after purchasing an additional 353 shares during the period. Daiwa Securities Group Inc. increased its position in IDEAYA Biosciences by 16.1% during the 2nd quarter. Daiwa Securities Group Inc. now owns 3,141 shares of the company’s stock worth $66,000 after purchasing an additional 436 shares in the last quarter. PNC Financial Services Group Inc. raised its holdings in IDEAYA Biosciences by 16.1% in the third quarter. PNC Financial Services Group Inc. now owns 3,881 shares of the company’s stock valued at $106,000 after buying an additional 537 shares during the period. CWM LLC raised its holdings in IDEAYA Biosciences by 33.0% in the second quarter. CWM LLC now owns 3,153 shares of the company’s stock valued at $66,000 after buying an additional 782 shares during the period. Finally, E Fund Management Co. Ltd. lifted its position in IDEAYA Biosciences by 7.8% during the second quarter. E Fund Management Co. Ltd. now owns 12,225 shares of the company’s stock valued at $257,000 after buying an additional 881 shares in the last quarter. Hedge funds and other institutional investors own 98.29% of the company’s stock.

IDEAYA Biosciences Price Performance

Shares of IDEAYA Biosciences stock opened at $32.90 on Friday. IDEAYA Biosciences, Inc. has a 1-year low of $13.45 and a 1-year high of $39.28. The company has a market capitalization of $2.89 billion, a PE ratio of -25.11 and a beta of 0.10. The business has a 50-day moving average of $34.23 and a 200-day moving average of $30.46.

IDEAYA Biosciences (NASDAQ:IDYA) last released its quarterly earnings results on Tuesday, February 17th. The company reported ($0.94) EPS for the quarter, topping the consensus estimate of ($1.03) by $0.09. The business had revenue of $21.75 million during the quarter, compared to analyst estimates of $5.95 million. During the same quarter last year, the firm posted ($1.49) EPS. The company’s revenue was up 55.7% compared to the same quarter last year. On average, equities analysts expect that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on IDYA shares. Weiss Ratings reissued a “sell (d-)” rating on shares of IDEAYA Biosciences in a research report on Thursday, January 22nd. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $49.00 price target on shares of IDEAYA Biosciences in a research report on Wednesday. Mizuho raised their price objective on IDEAYA Biosciences from $44.00 to $46.00 and gave the company an “outperform” rating in a research report on Tuesday, November 11th. Wall Street Zen upgraded IDEAYA Biosciences from a “hold” rating to a “buy” rating in a research note on Sunday, November 9th. Finally, JPMorgan Chase & Co. upped their target price on IDEAYA Biosciences from $74.00 to $79.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Fifteen analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $48.69.

IDEAYA Biosciences Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.